How is ri:val different from other valuation software?
ri:val is specifically conceived for the drug development industry. ri:val applies the most sophisticated valuation methods such as rNPV, real options, and Monte Carlo simulations to projects, licenses, pipelines, technologies, companies, and investment portfolios. ri:val’s user-friendly interface makes valuation easy, quick, and flexible. Avance, as a key opinion leader in valuation, makes sure that current developments in license structures are implemented and industry data are kept up-to-date. There is simply no comparable valuation solution in the life science industry. Some focus on valuation methods (e.g., Monte Carlo simulations) but do not provide any guidelines or data for drug development. Others are relatively inflexible and cannot cope with relatively simple license contracts. ri:val is the only valuation solution integrating project, pipeline, and technology valuation into a 360° company valuation and risk assessment.
